Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French Cohort Article Swipe
Jean-Baptiste Barbe-Richaud
,
Fabien Moinard‐Butot
,
Mathieu Cotton
,
C. Bigot
,
Pierre Rivière
,
Christine Belletier
,
Erwan Pencreach
,
Dan Karouby
,
Pascale Chiappa
,
Lauriane Eberst
,
J.E. Kurtz
,
Méher Ben Abdelghani
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/jcm14196759
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/jcm14196759
Background: Biliary tract cancer (BTC) management has undergone tremendous changes, benefiting from the identification of highly actionable molecular alterations. Among these, IDH1 mutations and FGFR2 fusions are the most common alterations detected and are classified as ESCAT tier 1 in BTC. However, their prognostic value in real-world settings remains uncertain. Objective: To explore overall survival (OS) in patients harbouring locally advanced or metastatic BTC (mBTC) with IDH1 or FGFR2 alterations, compared to those with wild-type tumours. Methods: This retrospective, multicentre study included patients with mBTC treated between 2020 and 2023 across five French centres. Patients were categorized into two cohorts based on molecular profiling: those with IDH1 or FGFR2 alterations, and those with wild-type tumours (WT-mBTC). Results: 119 consecutive patients were included. 18 were classified as altered (IDH1 = 13; FGFR2 = 5). Sixty-four pts underwent no molecular testing. The median OS of the entire cohort was 11.9 months (10.3–14.3). The median OS was 24.2 months (12.3–NA) versus 10.8 months (7.9–12.9), p = 0.02, in the altered and WT-mBTC cohorts, respectively. The Cox regression model conducted depicted an HR for death of 0.46 (CI95%, 0.2–0.9) for IDH1 or FGFR2 alterations. There were no diffence in PFS for first-line. Conclusions: Our cohort suggests that IDH1 or FGFR2 alterations may be associated with prognostic differences in patients with metastatic BTC, although they do not appear to influence outcomes under first-line treatment. These findings are consistent with trends observed in clinical trials. Whether improved survival is solely attributable to targeted therapies remains questionable. In line with ESMO recommendations, systematic molecular profiling should be considered in patients with mBTC.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/jcm14196759
- OA Status
- gold
- OpenAlex ID
- https://openalex.org/W4414511849
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414511849Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/jcm14196759Digital Object Identifier
- Title
-
Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French CohortWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-24Full publication date if available
- Authors
-
Jean-Baptiste Barbe-Richaud, Fabien Moinard‐Butot, Mathieu Cotton, C. Bigot, Pierre Rivière, Christine Belletier, Erwan Pencreach, Dan Karouby, Pascale Chiappa, Lauriane Eberst, J.E. Kurtz, Méher Ben AbdelghaniList of authors in order
- Landing page
-
https://doi.org/10.3390/jcm14196759Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.3390/jcm14196759Direct OA link when available
- Cited by
-
0Total citation count in OpenAlex
Full payload
| id | https://openalex.org/W4414511849 |
|---|---|
| doi | https://doi.org/10.3390/jcm14196759 |
| ids.doi | https://doi.org/10.3390/jcm14196759 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/41095838 |
| ids.openalex | https://openalex.org/W4414511849 |
| fwci | 0.0 |
| type | article |
| title | Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French Cohort |
| biblio.issue | 19 |
| biblio.volume | 14 |
| biblio.last_page | 6759 |
| biblio.first_page | 6759 |
| topics[0].id | https://openalex.org/T11364 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Cholangiocarcinoma and Gallbladder Cancer Studies |
| topics[1].id | https://openalex.org/T10231 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9994999766349792 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Pancreatic and Hepatic Oncology Research |
| topics[2].id | https://openalex.org/T12287 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9991999864578247 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Fibroblast Growth Factor Research |
| is_xpac | False |
| apc_list.value | 2400 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2598 |
| apc_paid.value | 2400 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2598 |
| language | en |
| locations[0].id | doi:10.3390/jcm14196759 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2737969411 |
| locations[0].source.issn | 2077-0383 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2077-0383 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Clinical Medicine |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Clinical Medicine |
| locations[0].landing_page_url | https://doi.org/10.3390/jcm14196759 |
| locations[1].id | pmid:41095838 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of clinical medicine |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/41095838 |
| locations[2].id | pmh:oai:europepmc.org:11336352 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12524672 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5098710838 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-1501-9391 |
| authorships[0].author.display_name | Jean-Baptiste Barbe-Richaud |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[0].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[0].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[0].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jean-Baptiste Barbe-Richaud |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[1].author.id | https://openalex.org/A5003322073 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5630-5220 |
| authorships[1].author.display_name | Fabien Moinard‐Butot |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[1].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[1].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[1].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Fabien Moinard-Butot |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[2].author.id | https://openalex.org/A5010599698 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Mathieu Cotton |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[2].affiliations[0].raw_affiliation_string | Service de Pharmacie, Institut de Cancérologie de Strasbourg Europe (ICANS), 67200 Strasbourg, France |
| authorships[2].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[2].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Mathieu Cotton |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Service de Pharmacie, Institut de Cancérologie de Strasbourg Europe (ICANS), 67200 Strasbourg, France |
| authorships[3].author.id | https://openalex.org/A5010048038 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | C. Bigot |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[3].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[3].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[3].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Cécile Bigot |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[4].author.id | https://openalex.org/A5102886486 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-2681-091X |
| authorships[4].author.display_name | Pierre Rivière |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[4].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[4].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[4].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Pierre Rivière |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[5].author.id | https://openalex.org/A5071110117 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Christine Belletier |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[5].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[5].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[5].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Christine Belletier |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[6].author.id | https://openalex.org/A5072224218 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Erwan Pencreach |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210145324 |
| authorships[6].affiliations[0].raw_affiliation_string | Département de Génétique Moléculaire des Cancers, Hôpitaux Universitaires de Strasbourg (HUS), 1 Avenue Molière, 67200 Strasbourg, France |
| authorships[6].institutions[0].id | https://openalex.org/I4210145324 |
| authorships[6].institutions[0].ror | https://ror.org/04bckew43 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210145324 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Hôpitaux Universitaires de Strasbourg |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Erwan Pencreach |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Département de Génétique Moléculaire des Cancers, Hôpitaux Universitaires de Strasbourg (HUS), 1 Avenue Molière, 67200 Strasbourg, France |
| authorships[7].author.id | https://openalex.org/A5043676009 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Dan Karouby |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[7].affiliations[0].raw_affiliation_string | Service de Pharmacie, Institut de Cancérologie de Strasbourg Europe (ICANS), 67200 Strasbourg, France |
| authorships[7].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[7].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Dan Karouby |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Service de Pharmacie, Institut de Cancérologie de Strasbourg Europe (ICANS), 67200 Strasbourg, France |
| authorships[8].author.id | https://openalex.org/A5041805167 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Pascale Chiappa |
| authorships[8].countries | FR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[8].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[8].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[8].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[8].institutions[0].country_code | FR |
| authorships[8].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Pascale Chiappa |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[9].author.id | https://openalex.org/A5090555713 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-0973-5954 |
| authorships[9].author.display_name | Lauriane Eberst |
| authorships[9].countries | FR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[9].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[9].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[9].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[9].institutions[0].country_code | FR |
| authorships[9].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Lauriane Eberst |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[10].author.id | https://openalex.org/A5110806533 |
| authorships[10].author.orcid | https://orcid.org/0009-0002-1923-8580 |
| authorships[10].author.display_name | J.E. Kurtz |
| authorships[10].countries | FR |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[10].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[10].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[10].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[10].institutions[0].country_code | FR |
| authorships[10].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Jean-Emmanuel Kurtz |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[11].author.id | https://openalex.org/A5005765894 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-9105-6346 |
| authorships[11].author.display_name | Méher Ben Abdelghani |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210090340 |
| authorships[11].affiliations[0].raw_affiliation_string | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| authorships[11].institutions[0].id | https://openalex.org/I4210090340 |
| authorships[11].institutions[0].ror | https://ror.org/008fdbn61 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210090340 |
| authorships[11].institutions[0].country_code | FR |
| authorships[11].institutions[0].display_name | Institut de Cancérologie Strasbourg |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Meher Ben Abdelghani |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Service D’oncologie Médicale, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200 Strasbourg, France |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.3390/jcm14196759 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French Cohort |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11364 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Cholangiocarcinoma and Gallbladder Cancer Studies |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.3390/jcm14196759 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2737969411 |
| best_oa_location.source.issn | 2077-0383 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2077-0383 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of Clinical Medicine |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Clinical Medicine |
| best_oa_location.landing_page_url | https://doi.org/10.3390/jcm14196759 |
| primary_location.id | doi:10.3390/jcm14196759 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2737969411 |
| primary_location.source.issn | 2077-0383 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2077-0383 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Clinical Medicine |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Clinical Medicine |
| primary_location.landing_page_url | https://doi.org/10.3390/jcm14196759 |
| publication_date | 2025-09-24 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.1 | 38 |
| abstract_inverted_index.= | 128, 131, 162 |
| abstract_inverted_index.p | 161 |
| abstract_inverted_index.18 | 122 |
| abstract_inverted_index.HR | 178 |
| abstract_inverted_index.In | 250 |
| abstract_inverted_index.OS | 141, 152 |
| abstract_inverted_index.To | 51 |
| abstract_inverted_index.an | 177 |
| abstract_inverted_index.as | 35, 125 |
| abstract_inverted_index.be | 208, 259 |
| abstract_inverted_index.do | 220 |
| abstract_inverted_index.in | 39, 45, 56, 164, 194, 213, 236, 261 |
| abstract_inverted_index.is | 242 |
| abstract_inverted_index.no | 136, 192 |
| abstract_inverted_index.of | 14, 142, 181 |
| abstract_inverted_index.on | 101 |
| abstract_inverted_index.or | 61, 67, 107, 187, 204 |
| abstract_inverted_index.to | 71, 223, 245 |
| abstract_inverted_index.119 | 117 |
| abstract_inverted_index.13; | 129 |
| abstract_inverted_index.5). | 132 |
| abstract_inverted_index.BTC | 63 |
| abstract_inverted_index.Cox | 172 |
| abstract_inverted_index.Our | 199 |
| abstract_inverted_index.PFS | 195 |
| abstract_inverted_index.The | 139, 150, 171 |
| abstract_inverted_index.and | 23, 32, 88, 110, 167 |
| abstract_inverted_index.are | 26, 33, 231 |
| abstract_inverted_index.for | 179, 185, 196 |
| abstract_inverted_index.has | 6 |
| abstract_inverted_index.may | 207 |
| abstract_inverted_index.not | 221 |
| abstract_inverted_index.pts | 134 |
| abstract_inverted_index.the | 12, 27, 143, 165 |
| abstract_inverted_index.two | 98 |
| abstract_inverted_index.was | 146, 153 |
| abstract_inverted_index.(OS) | 55 |
| abstract_inverted_index.0.46 | 182 |
| abstract_inverted_index.10.8 | 158 |
| abstract_inverted_index.11.9 | 147 |
| abstract_inverted_index.2020 | 87 |
| abstract_inverted_index.2023 | 89 |
| abstract_inverted_index.24.2 | 154 |
| abstract_inverted_index.BTC, | 217 |
| abstract_inverted_index.BTC. | 40 |
| abstract_inverted_index.ESMO | 253 |
| abstract_inverted_index.IDH1 | 21, 66, 106, 186, 203 |
| abstract_inverted_index.This | 77 |
| abstract_inverted_index.five | 91 |
| abstract_inverted_index.from | 11 |
| abstract_inverted_index.into | 97 |
| abstract_inverted_index.line | 251 |
| abstract_inverted_index.mBTC | 84 |
| abstract_inverted_index.most | 28 |
| abstract_inverted_index.that | 202 |
| abstract_inverted_index.they | 219 |
| abstract_inverted_index.tier | 37 |
| abstract_inverted_index.were | 95, 120, 123, 191 |
| abstract_inverted_index.with | 65, 73, 83, 105, 112, 210, 215, 233, 252, 263 |
| abstract_inverted_index.(BTC) | 4 |
| abstract_inverted_index.(IDH1 | 127 |
| abstract_inverted_index.0.02, | 163 |
| abstract_inverted_index.Among | 19 |
| abstract_inverted_index.ESCAT | 36 |
| abstract_inverted_index.FGFR2 | 24, 68, 108, 130, 188, 205 |
| abstract_inverted_index.There | 190 |
| abstract_inverted_index.These | 229 |
| abstract_inverted_index.based | 100 |
| abstract_inverted_index.death | 180 |
| abstract_inverted_index.mBTC. | 264 |
| abstract_inverted_index.model | 174 |
| abstract_inverted_index.study | 80 |
| abstract_inverted_index.their | 42 |
| abstract_inverted_index.those | 72, 104, 111 |
| abstract_inverted_index.tract | 2 |
| abstract_inverted_index.under | 226 |
| abstract_inverted_index.value | 44 |
| abstract_inverted_index.(mBTC) | 64 |
| abstract_inverted_index.French | 92 |
| abstract_inverted_index.across | 90 |
| abstract_inverted_index.appear | 222 |
| abstract_inverted_index.cancer | 3 |
| abstract_inverted_index.cohort | 145, 200 |
| abstract_inverted_index.common | 29 |
| abstract_inverted_index.entire | 144 |
| abstract_inverted_index.highly | 15 |
| abstract_inverted_index.median | 140, 151 |
| abstract_inverted_index.months | 148, 155, 159 |
| abstract_inverted_index.should | 258 |
| abstract_inverted_index.solely | 243 |
| abstract_inverted_index.these, | 20 |
| abstract_inverted_index.trends | 234 |
| abstract_inverted_index.versus | 157 |
| abstract_inverted_index.(CI95%, | 183 |
| abstract_inverted_index.Biliary | 1 |
| abstract_inverted_index.WT-mBTC | 168 |
| abstract_inverted_index.Whether | 239 |
| abstract_inverted_index.altered | 126, 166 |
| abstract_inverted_index.between | 86 |
| abstract_inverted_index.cohorts | 99 |
| abstract_inverted_index.explore | 52 |
| abstract_inverted_index.fusions | 25 |
| abstract_inverted_index.locally | 59 |
| abstract_inverted_index.overall | 53 |
| abstract_inverted_index.remains | 48, 248 |
| abstract_inverted_index.treated | 85 |
| abstract_inverted_index.trials. | 238 |
| abstract_inverted_index.tumours | 114 |
| abstract_inverted_index.However, | 41 |
| abstract_inverted_index.Methods: | 76 |
| abstract_inverted_index.Patients | 94 |
| abstract_inverted_index.Results: | 116 |
| abstract_inverted_index.advanced | 60 |
| abstract_inverted_index.although | 218 |
| abstract_inverted_index.centres. | 93 |
| abstract_inverted_index.changes, | 9 |
| abstract_inverted_index.clinical | 237 |
| abstract_inverted_index.cohorts, | 169 |
| abstract_inverted_index.compared | 70 |
| abstract_inverted_index.depicted | 176 |
| abstract_inverted_index.detected | 31 |
| abstract_inverted_index.diffence | 193 |
| abstract_inverted_index.findings | 230 |
| abstract_inverted_index.improved | 240 |
| abstract_inverted_index.included | 81 |
| abstract_inverted_index.observed | 235 |
| abstract_inverted_index.outcomes | 225 |
| abstract_inverted_index.patients | 57, 82, 119, 214, 262 |
| abstract_inverted_index.settings | 47 |
| abstract_inverted_index.suggests | 201 |
| abstract_inverted_index.survival | 54, 241 |
| abstract_inverted_index.targeted | 246 |
| abstract_inverted_index.testing. | 138 |
| abstract_inverted_index.tumours. | 75 |
| abstract_inverted_index.conducted | 175 |
| abstract_inverted_index.included. | 121 |
| abstract_inverted_index.influence | 224 |
| abstract_inverted_index.molecular | 17, 102, 137, 256 |
| abstract_inverted_index.mutations | 22 |
| abstract_inverted_index.profiling | 257 |
| abstract_inverted_index.therapies | 247 |
| abstract_inverted_index.undergone | 7 |
| abstract_inverted_index.underwent | 135 |
| abstract_inverted_index.wild-type | 74, 113 |
| abstract_inverted_index.(WT-mBTC). | 115 |
| abstract_inverted_index.0.2–0.9) | 184 |
| abstract_inverted_index.Objective: | 50 |
| abstract_inverted_index.Sixty-four | 133 |
| abstract_inverted_index.actionable | 16 |
| abstract_inverted_index.associated | 209 |
| abstract_inverted_index.benefiting | 10 |
| abstract_inverted_index.classified | 34, 124 |
| abstract_inverted_index.considered | 260 |
| abstract_inverted_index.consistent | 232 |
| abstract_inverted_index.first-line | 227 |
| abstract_inverted_index.harbouring | 58 |
| abstract_inverted_index.management | 5 |
| abstract_inverted_index.metastatic | 62, 216 |
| abstract_inverted_index.profiling: | 103 |
| abstract_inverted_index.prognostic | 43, 211 |
| abstract_inverted_index.real-world | 46 |
| abstract_inverted_index.regression | 173 |
| abstract_inverted_index.systematic | 255 |
| abstract_inverted_index.treatment. | 228 |
| abstract_inverted_index.tremendous | 8 |
| abstract_inverted_index.uncertain. | 49 |
| abstract_inverted_index.(12.3–NA) | 156 |
| abstract_inverted_index.Background: | 0 |
| abstract_inverted_index.alterations | 30, 206 |
| abstract_inverted_index.categorized | 96 |
| abstract_inverted_index.consecutive | 118 |
| abstract_inverted_index.differences | 212 |
| abstract_inverted_index.first-line. | 197 |
| abstract_inverted_index.multicentre | 79 |
| abstract_inverted_index.Conclusions: | 198 |
| abstract_inverted_index.alterations, | 69, 109 |
| abstract_inverted_index.alterations. | 18, 189 |
| abstract_inverted_index.attributable | 244 |
| abstract_inverted_index.(7.9–12.9), | 160 |
| abstract_inverted_index.questionable. | 249 |
| abstract_inverted_index.respectively. | 170 |
| abstract_inverted_index.(10.3–14.3). | 149 |
| abstract_inverted_index.identification | 13 |
| abstract_inverted_index.retrospective, | 78 |
| abstract_inverted_index.recommendations, | 254 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 12 |
| citation_normalized_percentile.value | 0.63891942 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |